019170 — SHINPOONG PHARMACEUTICAL CO Income Statement
0.000.00%
Last trade - 00:00- KR₩486bn
- KR₩486bn
- KR₩221bn
Annual income statement for SHINPOONG PHARMACEUTICAL CO, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 197,751 | 189,237 | 209,288 | 200,229 | 221,094 |
| Cost of Revenue | |||||
| Gross Profit | 76,527 | 77,388 | 77,973 | 80,277 | 81,804 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 190,937 | 203,544 | 245,883 | 247,260 | 241,550 |
| Operating Profit | 6,814 | -14,306 | -36,596 | -47,031 | -20,455 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 8,340 | -8,986 | -34,782 | -53,442 | -14,622 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 5,046 | -11,526 | -35,309 | -57,273 | -15,373 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 5,003 | -11,584 | -35,377 | -57,325 | -15,387 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 4,774 | -11,165 | -34,034 | -55,127 | -14,821 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 112 | -227 | -657 | -1,124 | -301 |
| Dividends per Share |